Bristol-Myers Squibb Settles FCPA Case for $14 Million
Pharmaceutical giant Bristol-Myers Squibb has reached a $14 million settlement with the SEC for violations of the Foreign Corrupt Practices Act. According to the Commission, the company’s joint venture in China made cash payments and provided other benefits to healthcare providers at state-owned and state-controlled hospitals in exchange for prescription ...
Related articles
-
Blog
Justice Department Ends Bristol-Myers Squibb FCPA Probe
The Department of Justice has ended its investigation into allegations that pharmaceutical giant Bristol-Myers Squibb violated the Foreign Corrupt Practices Act. Earlier this month the company reached a $14 million settlement with the SEC for FCPA violations relating to certain sales and marketing practices in China. More inside.
-
News BriefSEC reportedly investigating MassMutual’s accounting amid ongoing government shutdown
Even though the U.S. federal government is currently shut down, the U.S. Securities and Exchange Commission appears to still be at work. The financial regulator is reportedly investigating a major insurance and asset management company over its accounting practices.
-
ArticleU.K. enforcement appetite over off-channel comms grows as U.S. wanes
The U.K’.s financial regulator has given a strong indication that financial firms’ use of unauthorized devices and apps is under scrutiny and that policies around off-channel communications need to be tightened up.